I agree kbear, my gut feel is that they know the ICS data is good and that we are going to be opened up to other cancer markets. I also think that the phase 11b data is probably too early in the trials to provide any really meaningful data re: efficacy
With the potential for treating other cancers, the target market is gigantic, and I'm now starting to feel that takeover interest from big pharma is not far away
biox webcast is up, page-10
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.005(1.61%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.8¢ | $684.8K | 2.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 436502 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 92443 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |